ipratropium bromide

CLINICAL USE

Anticholinergic bronchodilator:Reversible airways obstruction, particularly in COPD

DOSE IN NORMAL RENAL FUNCTION

Nebuliser solution: 250–500 micrograms 3– 4 times dailyInhaler: 20–80 micrograms 3–4 times daily

PHARMACOKINETICS

Molecular weight :430.4

%Protein binding :<20

%Excreted unchanged in urine : <1

Volume of distribution (L/kg) :4.6

half-life – normal/ESRD (hrs) :1.6/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Not dialysed. Dose as in normal renal function

CAV/VVHD :Not dialysed. Dose as normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Inhaled

Rate of Administration

Nebuliser: according to nebuliser

Comments

The dose of nebuliser solution may need to be diluted in order to obtain a final volume suitable for the nebuliserSterile sodium chloride 0.9% should be used if dilution is required

OTHER INFORMATION

Following inhalation, only a small amount of ipratropium reaches the systemic circulation. Any swallowed drug is poorly absorbed from the GI tract

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home